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Abstract
The clinical and microbiological characteristics of community-onset healthcare-associated (HCA) bacteraemia of urinary source are not well
deﬁned. We conducted a prospective cohort study at eight tertiary-care hospitals in Spain, from October 2010 to June 2011. All
consecutive adult patients hospitalized with bacteraemic urinary tract infection (BUTI) were included. HCA-BUTI episodes were compared
with community-acquired (CA) and hospital-acquired (HA) BUTI. A logistic regression analysis was performed to identify 30-day mortality
risk factors. We included 667 episodes of BUTI (246 HCA, 279 CA and 142 HA). Differences between HCA-BUTI and CA-BUTI were
female gender (40% vs 69%, p <0.001), McCabe score II–III (48% vs 14%, p <0.001), Pitt score  2 (40% vs 31%, p 0.03), isolation of
extended spectrum b-lactamase-producing Enterobacteriaciae (13% vs 5%, p <0.001), median hospital stay (9 vs 7 days, p 0.03),
inappropriate empirical antimicrobial therapy (21% vs 13%, p 0.02) and mortality (11.4% vs 3.9%, p 0.001). Pseudomonas aeruginosa was
more frequently isolated in HA-BUTI (16%) than in HCA-BUTI (4%, p <0.001). Independent factors for mortality were age (OR 1.04; 95%
CI 1.01–1.07), McCabe score II–III (OR 3.2; 95% CI 1.8–5.5), Pitt score  2 (OR 3.2 (1.8–5.5) and HA-BUTI OR 3.4 (1.2–9.0)). Patients with
HCA-BUTI are a speciﬁc group with signiﬁcant clinical and microbiological differences from patients with CA-BUTI, and some similarities
with patients with HA-BUTI. Mortality was associated with patient condition, the severity of infection and hospital acquisition.
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Introduction
Urinary tract infections (UTI) are one of the most frequent
bacterial infections in the community and in hospitals. It has
an estimated overall incidence rate of 17.5 per 1000
person-years [1]. Around 1 million cases of nosocomial
UTI occur in the USA annually [2]. In the Spanish national
prevalence study (EPINE) performed annually since 1990
UTI represented between 26% of nosocomial infections in
the 1990s and 20% in 2011 [3]. Between 15% and 25% of
episodes of UTI have positive blood cultures at the time of
presentation [4–6]. In bacteraemic episodes mortality
can vary between 4% and 30% depending on baseline
conditions and age. Inadequate or delayed antimicrobial
treatment might inﬂuence the outcome under some cir-
cumstances [6–9].
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In the last years, there have been important changes in
healthcare delivery. Some traditionally inpatient procedures
are now routinely performed on an outpatient basis. Infections
acquired by these patients cannot be classiﬁed as hospital-
acquired (HA) or community-acquired (CA), so they have
been named healthcare-associated (HCA) infections [10].
Recent studies of bloodstream infections, pneumonia and
endocarditis have shown that community-onset HCA infec-
tions are more similar to HA than to CA infections [10–13].
Taking into account this classiﬁcation, there is little informa-
tion regarding bacteraemia of urinary source and its possible
impact on healthcare delivery. It is a matter of concern that
rates of bacterial resistance of uropathogens have signiﬁcantly
increased worldwide [14]. This has important implications not
only in acute uncomplicated UTI [15], but also in bacteraemic
forms (BUTI) [16]. Delay in appropriate antimicrobial therapy
can lead to adverse outcomes and potentially increased
mortality, a longer hospital stay, and higher costs in patients
with severe forms of UTI [9,17,18].
The aim of this study is to describe the epidemiological,
clinical and microbiological features and appropriateness of
empirical antimicrobial therapy in patients with HCA-BUTI by
means of a prospective multicentre study. We also compared
HCA with HA-BUTI and CA-BUTI, and assessed mortality-
related factors.
Materials and Methods
Setting and patients
A prospective cohort observational study was conducted at
eight tertiary-care hospitals in Spain (total beds 6500 and
inhabitant coverage of 3 701 600). We included all consecu-
tive patients over 18 years of age with BUTI requiring
hospitalization or those who were already hospitalized and
developed BUTI from October 2010 up to June 2011.
Exclusion criteria included bacteraemia from another source
or primary bacteraemia. Cases were identiﬁed from a
prospective clinical chart review of all patients with a potential
uropathogen isolated in blood cultures reported daily by
microbiology laboratories in each hospital. Enterobacteriaceae,
Pseudomonas aeruginosa, other non-fermenteing gram-negative
bacilli, Enterococcus spp. and Staphylococcus saprophyticus were
considered potential uropathogens. Assessment was per-
formed by the local investigator in each centre following the
same criteria. Patients were followed up until 30 days after the
bacteraemic episode.
Sample size was calculated to detect differences in the
appropriateness of empirical antimicrobial therapy between
CA-BUTI and HCA-BUTI. Taking into account a signiﬁcance
level of 95%, a power of 80% and 10% losses, and based on our
previous experience [19], to detect a difference of 8% in the
appropriateness of empirical antimicrobial therapy between
CA-BUTI (15%) and HCA-BUTI (23%), sample size should be
210 patients per branch. This sample size is large enough to
detect a difference in mortality between the two groups of 6%
(4% vs 10%).
Study variables
Main outcome variable: 30-day all-cause mortality.
Explanatory variables: Demographic characteristics, the McCabe
Score [20], urological history, previous antibiotic therapy,
clinical symptoms, the Pitt Score [21] assessed at the time of
positive blood culture, causative microorganisms, antibiotic
susceptibilities, empirical treatment and the length of stay.
Deﬁnitions
BUTI was deﬁned following the CDC/National Healthcare
Safety Network (NHSN) bacteraemia deﬁnition criteria plus
accompanying symptomatic UTI (urinary tract symptoms that
included dysuria, frequency, gross haematuria, ﬂank or abdom-
inal pain) with or without positive urine culture (>105 CFU/mL)
or asymptomatic UTI with the isolation of the same uropatho-
gen in a urine culture (NHSN Speciﬁc infection type—
asymptomatic bacteraemic urinary tract infection) [22].
HCA-BUTI was deﬁned as an episode detected at hospital
admission or within the ﬁrst 48 h after admission, which fulﬁlled
any of the following Friedman criteria with modiﬁcations [23]:
(i) Receiving intravenous therapy, wound care or specialized
nursing care at home by qualiﬁed healthcare workers within
30 days of the episode. (ii) Attending a hospital, haemodialysis
ward or receiving intravenous chemotherapy within 30 days of
the episode. (iii) Being hospitalized in an acute-care hospital for
2 or more days within 90 days of current hospitalization. (iv)
Residing in a nursing home or long-term care facility. (v) Being
subjected to an invasive urinary procedure within 30 days of
the episode or having a long-term indwelling urethral catheter.
CA-BUTI was deﬁned as episodes detected at hospital
admission or within the ﬁrst 48 h without fulﬁlling any of the
above criteria for HCA-BUTI.
Episodes detected beyond 48 h of hospital admission were
considered HA-BUTI.
Prior antibiotic therapy was deﬁned as antibiotics given for at
least 2 days within the previous 90 days before the episode.
These data were collected by direct interview with the patient
or the family if that information was not in the clinical chart.
Severe sepsis or septic shock was deﬁned according to the
2001 International Sepsis Deﬁnitions Conference [24].
Appropriate empirical treatment was considered if the initial
treatment regimen included one or more antibiotics with in
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vitro activity against the causative microorganism within 24 h of
blood culture collection.
Bacteraemia-related in-hospital mortality was considered if the
patient died during hospitalization, and the clinician evaluating
the patient at the time of death documented bacteraemia as
the cause of death and the patient did not have another more
prominent cause of death.
Microbiological studies
Bacteria were isolated from blood cultures and urine samples
in accordance with local protocols in each centre. Bacterial
identiﬁcation and antimicrobial susceptibility tests were per-
formed in each centre with standardized methods, using either
automated systems, manual systems or both, depending on the
isolated species. Each laboratory implements internal controls
according to their quality control programmes. Moreover,
Microbiology Departments participate in an external quality
control programme for the Spanish Society of Infectious
Diseases and Clinical Microbiology (SEIMC) (http://www.
seimc.org/control/). Antimicrobial susceptibility results were
interpreted according to CLSI criteria [25]. Fluoroquinolone
resistance was deﬁned as resistance to ciproﬂoxacin. Extended
spectrum b-lacatamase (ESBL) phenotypic production was
assessed following the methodologies recommended by CLSI
[25]. Microbiological data relative to bacterial identiﬁcation,
the antimicrobial susceptibility proﬁle and ESBL production
were collected at each study site.
Ethics
The study protocol was reviewed and approved by the Clinical
Research Ethics Committee of the Parc de Salut MAR,
Barcelona.
Statistical analysis
The chi-squared test was used to compare categorical data and
the Student’s t test or Mann–Whitney U test was used for
continuous data. A logistic regression analysis was performed
to identify risk factors associated with 30-day mortality.
Variables with p <0.10 in bivariate analysis were included in
the multivariate analysis. The adequacy of the ﬁnal model was
tested with the Hosmer–Lemeshow goodness of ﬁt. All tests
were two-tailed, and a p value <0.05 was considered
statistically signiﬁcant. Data were analysed with SPSS 18.0.
Results
During the study period, 2323 bacteraemia episodes with a
potential uropathogen were identiﬁed and 667 fulﬁlled the
inclusion criteria. Of these, 279 (42%) were CA, 246 (37%)
were HCA and 142 (21%) were HA. Fig. 1 shows the study
recruitment ﬂow-chart.
The distribution of the risk categories in the HCA group
(n = 246) was as follows:
hospitalization within the previous 90 days 145 (59%),
urological procedure within the previous 30 days 85 (35%),
residence in a long-term care facility within the previous
30 days 50 (20%), intravenous therapy within the previous
30 days 25 (10%), home wound care within the previous
30 days 10 (4%), haemodialysis within the previous 30 days 4
(1.6%) and outpatient abdominal surgery within the 30
previous days 2 (0.8%). Sixty-four patients (25%) had more
than one risk factor.
Patients with CA-BUTI and HCA-BUTI were admitted on
to the following hospital wards: medical 357 (68%), surgical 94
(17.9%), intensive care 41 (7.8%) and oncology–haematology
33 (6.3%). Patients with HA-BUTI were hospitalized on the
following hospital wards: medical 56 (39.4%), surgical 48
(33.8%), intensive care 17 (12%), oncology–haematology 21
(14.8%).
Clinical characteristics and outcome
In comparison to CA-BUTI, patients with HCA-BUTI were
predominantly male and had a higher debilitating condition
score. Furthermore, previous antimicrobial therapy was
signiﬁcantly more frequent in patients with HCA-BUTI than
in patients with CA-BUTI. These differences did not exist
when compared with HA-BUTI. Anatomical or functional
urinary tract abnormalities and history of recurrent urinary
infections were more frequent in the HCA group (Table 1).
Speciﬁc urinary tract symptoms were less frequent in patients
with HCA-BUTI compared with those with CA-BUTI. How-
ever, the latter had a higher Pitt score at presentation. Fewer
differences between HCA and HA infections were found
(Table 2).
The most frequently chosen empirical antimicrobials in the
groups were a combination of b-lactam with a b-lactamase
inhibitor (amoxicillin/clavulanate 22% and piperacillin/tazobac-
tam 14%) followed by cephalosporins 27%, carbapenems 20%
and ﬂuoroquinolones 11%).
Inappropriate empirical therapy was signiﬁcantly more
frequent in HCA-BUTI (21%) and in HA-BUTI (28%) than in
CA-BUTI episodes (13%) (Table 2). Hospital stay and all-cause
30-day hospital mortality were different in the three groups
with a higher rate in the HCA and HA groups (Table 2).
Microbiology
Escherichia coli was the most frequent isolated microorganism
in the three groups, but there were signiﬁcant differences
between them (82% in CA, 72% in HCA and 49% in HA,
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Table 3). ESBL-producing Enterobacteriaceae, isolated in 62
out of 667 episodes (9%), were present less frequently in
patients with CA-BUTI (5%) than in those with HCA-BUTI
(13%) and HA-BUTI (12%) episodes. Enterobacteriaceae
resistant to quinolones were quite frequent in HCA-BUTI
(50%) and signiﬁcantly more frequent than in CA-BUTI (25%).
Resistance to amoxicillin-clavulanate and piperacillin-tazobac-
tam was signiﬁcantly more frequent in the HCA and HA group
than in the CA group (Table 3).
ESBL-producing Enterobacteriaceae also resistant to ﬂuor-
oquinolones or amoxicillin-clavulanate were isolated in 93% and
81%, respectively. P. aeruginosa and other Enterobacteriaceae
Bacteraemia  by potential uropathogens, n = 2323 
Included, n = 667 (29%)
Community-acquired, n = 279 (42%) 
Community onset, n = 246 (63%) 
Excluded, n = 1656 (71%) 
- Hospitalization not required, n = 207
- Different source, n = 1449 
Healthcare-associated, n = 388 (58%) 
Hospital-acquired, n = 142 (37%) 
FIG. 1. Flow chart of bacteraemic urinary tract infection recruitment.
TABLE 1. Baseline demographics and underlying conditions
of patients with bacteraemic urinary tract infection by the
site of acquisition
HCA
n = 246
CA
n = 279 p*
HA
n = 142 p**
Age, median
(range)
years
77 (24–103) 76 (19–97) 0.04 74 (21–92) 0.09
Age, mean (SD)
years
74 (13) 69 (18) 0.04 72 (12.5) 0.15
Gender, female 99 (40) 191 (69) <0.001 47 (33) 0.16
McCabe score II–III 119 (48) 40 (14) <0.001 67 (47) 0.82
Recurrent UTI
(>2 episodes/year)
80 (33) 58 (21) 0.002 23 (16) <0.001
Urinary tract
obstruction
historya
82 (33) 64 (23) 0.008 37 (26) 0.13
Urological
neoplasm
64 (26) 26 (9) <0.001 23 (16) 0.03
Indwelling urethral
catheter
66 (27) – – 98 (69) <0.001
Structural or
functional
urinary tract
abnormalitiesb
62 (25) 17 (6) <0.001 24 (17) 0.06
Antimicrobial
therapy
in the previous
90 days
146 (59) 61 (22) <0.001 80 (56) 0.18
HCA, community-onset healthcare-associated; CA community-acquired; HA
hospital-acquired. Data are given as numbers (%), unless otherwise indicated.
*Comparison between HCA and CA.
**Comparison between HCA and HA.
aUrinary tract obstruction included calculi and prostatic enlargement.
bDeﬁned as any functional or anatomical abnormality of the urinary tract excluding
the presence of urethral catheters or urinary tract obstruction history.
TABLE 2. Clinical characteristics and outcome of patients
with bacteraemic urinary tract infection by the site of
acquisition
HCA
n = 246
CA
n = 279 p*
HA
n = 142 p**
Speciﬁc urinary tract
symptomsa
94 (38) 183 (66) <0.001 31 (22) 0.001
Temperature >38°C 222 (90) 241 (86) 0.17 116 (82) 0.02
White blood cell
count
(<4000 or >12000
leucocytes/mm3)
167 (68) 174 (63) 0.20 90 (63) 0.59
Pitt score  2 98 (40) 86 (31) 0.03 52 (37) 0.53
Severe sepsis or
septic shock
91 (37) 84 (30) 0.09 45 (32) 0.29
ICU admission 28 (11) 40 (14) 0.31 16 (11) 0.97
Urological
intervention
requiredb
32 (13) 42 (15) 0.50 14 (10) 0.36
Inappropriate
empirical
therapy
51 (21) 36 (13) 0.02 40 (28) 0.10
Median length of
stay (range) days
9 (1–66) 7 (0–47) 0.02 13 (0–87) <0.001
Bacteraemia-related
in-hospital
mortality
12 (5) 5 (2) 0.05 13 (9) 0.10
All-cause in-hospital
mortality
24 (10) 9 (3) 0.002 27 (19) 0.009
All-cause 30-day
mortality
28 (11.4) 11 (3.9) 0.001 29 (20.4) 0.01
HCA, community-onset healthcare-associated; CA, community-acquired; HA
hospital-acquired. Data are given as numbers (%), unless otherwise indicated.
*Comparison between HCA and CA.
**Comparison between HCA and HA.
aSpeciﬁc urinary tract symptoms included dysuria, frequency, gross haematuria,
ﬂank or abdominal pain.
bIncluded endoscopic, percutaneous or surgical drainage, and nephrectomy.
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such as Enterobacter spp., Citrobacter spp., Morganella spp. or
Serratia spp. were more frequently isolated in patients with HA-
BUTI, but not from patients in the HCA group (Table 3).
Mortality risk factors
The bivariate analysis showed that 30-day mortality was
associated with age, the McCabe score II–III, an indwelling
urethral catheter, the site of infection acquisition, a Pitt score
 2, severe sepsis or septic shock and P. aeruginosa isolation.
Multivariate analysis showed age (OR 1.04; 95% CI 1.01–1.07),
a McCabe score II–III (ultimately or rapidly fatal disease) (OR
3.2; 95% CI 1.8–5.5), a Pitt score  2 (OR 3.2; 95% CI 1.8–5.5)
and HA-BUTI (3.4; 95% CI 1.2–9.0) as independent factors in
terms of 30-day mortality. A microorganism resistant proﬁle
and inappropriate empirical therapy were not associated with
30-day mortality. (Table 4).
Discussion
Our study shows that patients with HCA-BUTI have more
comorbidities, urinary tract abnormalities and recurrent UTI,
and have previously received antibiotics more often than
patients with CA-BUTI. They also have less speciﬁc urinary
tract symptoms. Of note, the mortality rate and length of
hospital stay were signiﬁcantly higher in HCA-BUTI than in
CA-BUTI in the bivariate analysis. This was also shown in a
previous study, even after adjusting for age [16]. This might be
explained by the underlying chronic medical conditions and
acute severity of illness as the multivariate analysis of mortality
demonstrates. Other studies of bacteraemia have demon-
strated an association between inappropriate empirical anti-
microbial therapy and mortality [26,27], but this was not the
case in our series. This is probably a result of the low mortality
rate of BUTI [28], and because of the sample size of our
cohort, which could not be powered to detect this association.
How healthcare-related acquisition of the infection might
inﬂuence the risk of death is not entirely clear.
In UTI, previous antimicrobial therapy, urological proce-
dures, the use of urinary catheters and a prolonged hospital
stay have been considered risk factors for developing infec-
tions due to microorganisms other than E. coli and antibiotic-
resistant microorganisms [29–31]. However, how the site of
infection acquisition may affect the characteristics of bacte-
raemic UTI has not been previously assessed. In our series, the
distribution of common uropathogens in the three groups
shows a staggered pattern, with more E. coli in the CA group,
as in a previous study.[16] Interestingly, in our series
important differences in the frequency of antimicrobial-resis-
tant uropathogens, including ESBL-producing, amoxicillin-cla-
vulanic acid-resistant, and ﬂuoroquinolone-resistant
Enterobacteriaceae, were shown. In contrast to CA-BUTI,
HCA-BUTI and HA-UTI were more frequently caused by
these resistant pathogens. This may have some implications for
TABLE 3. Uropathogens isolated from blood cultures of
patients with bacteraemic urinary tract infection by site of
acquisition
HCA
n = 246
CA
n = 279 p*
HA
n = 142 p**
Escherichia coli 176 (72) 230 (82) 0.003 70 (49) <0.001
Klebsiella spp. 30 (12) 21 (8) 0.07 22 (16) 0.36
Proteus spp. 15 (6) 16 (6) 0.86 3 (2) 0.07
Other Enterobacteriaceaea 9 (4) 4 (1) 0.06 14 (10) 0.02
Pseudomonas aeruginosa 9 (4) 5 (2) 0.18 23 (16) <0.001
Enterococcus spp. 11 (5) 6 (2) 0.13 12 (9) 0.11
Polymicrobial bacteraemia 6 (2) 2 (1) 0.11 2 (1) 0.72
ESBL*-E. coli 24 (10) 10 (4) 0.004 10 (7) 0.36
ESBL*-Klebsiella spp. 6 (2) 2 (1) 0.15 5 (3) 0.54
ESBL*-producing
Enterobacteriaceae
33 (13) 12 (5) <0.001 17 (12) 0.68
Fluoroquinolone-resistant
Enterobacteriaceae
124 (50) 69 (25) <0.001 51 (36) 0.006
Amoxicillin/clavulanate-
resistant
Enterobacteriaceae
73 (30) 52 (19) 0.003 45 (32) 0.68
Piperacillin/tazobactam-
resistant
Enterobacteriaceae
37 (16) 19 (7) 0.001 27 (25) 0.06
HCA, community-onset healthcare-associated; CA, community-acquired; HA
hospital-acquired. Data are given as numbers (%), unless otherwise indicated.
*Comparison between HCA and CA.
**Comparison between HCA and HA. aHCA isolates: Enterobacter spp. (n = 1),
Citrobacter spp (n = 2), Morganella spp. (n = 2), Providencia spp. (n = 2), Serratia
spp. (n = 2). CA isolates: Enterobacter spp. (n = 1), Citrobacter spp. (n = 2),
Morganella spp. (n = 1). HA isolates: Enterobacter spp. (n = 8), Citrobacter spp.
(n = 2), Morganella spp. (n = 3), Serratia spp. (n = 1). *ESBL: extended-spectrum
b-lactamase-producing Enterobacteriaceae.
TABLE 4. Bivariate and multivariate analysis of predictors of
all cause 30-day mortality in the 667 patients of the cohort
study
OR unadjusted
(95% CI)
OR adjusted
(95% CI) p*
Age, years 1.04 (1.02–1.07) 1.04 (1.01–1.07) 0.001
Sex, male 1.8 (1.1–3.1) 1.4 (0.8–2.7) 0.20
McCabe II–III (ultimately
or ﬁnally fatal disease)
4.8 (2.8–8.3) 3.2 (1.8–5.5) 0.001
Urinary tract obstruction
historya
1.4 (0.8–2.3) –
Urological neoplasm 1.6 (0.8–2.9) –
Indwelling urethral
catheter
2.9 (1.7–4.9) 1.0 (0.5–2.2) 0.74
Site of acquisitionb
HCA 3.1 (1.5–6.4) 1.6 (0.7–3.6) 0.23
HA 6.2 (3.0–12.9) 3.4 (1.2–9.0) 0.01
Pitt score,  2 3.3 (2.0–5.6) 3.2 (1.8–5.5) <0.001
Severe sepsis or septic
shock
3.1 (1.8–5.1) –
ICU admission 0.9 (0.4–1.9) –
Pseudomonas aeruginosa 3.1 (1.4–6.9) 1.9 (0.7–4.8) 0.15
ESBL-Enterobacteriaceae 1.5 (0.7–3.3) –
ESBL-Escherichia coli 2.0 (0.8–4.7) –
ESBL-Klebsiella spp. 0.8 (0.1–6.6) –
Inappropriate empirical
therapy
1.2 (0.6–2.2) –
HCA, community-onset healthcare-associated; HA, hospital-acquired; ESBL,
extended-spectrum b-lactamase-producing Enterobacteriaceae.
Variables with p <0.10 in bivariate analysis were entered in multivariate analysis.
*It shows p-value of variables included in the ﬁnal model.
aUrinary tract obstruction included calculi and prostatic enlargement.
bReference category: community-acquired.
Homer–Lemeshow test for goodness of ﬁt for the logistic regression model,
p 0.541.
Severe sepsis/septic shock was not included in the ﬁnal model because there was a
high correlation (0.7) with the Pitt bacteraemia score.
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empirical antimicrobial therapy. In fact, empirical antibiotic
therapy was more frequently inappropriate in HCA-BUTI than
in CA-BUTI patients. These ﬁndings suggest that patients with
HCA-BUTI should be considered different from patients with
CA-BUTI to avoid treatment failure, and in some instances,
higher morbidity and mortality [32]. Isolation of P. aeruginosa
was signiﬁcantly more frequent in patients with HA-BUTI, as
older series had previously shown, but it was not so frequent
in HCA-BUTI patients as might have been expected. Although
the frequency of isolation of Enterococcus spp. was somewhat
higher in the HA group, there were no statistical differences
between the three groups.
This study conﬁrms that patients with HCA-BUTI are under-
recognized as a speciﬁc group of outpatients with invasive
infection presenting clinical andmicrobiological differences from
CA-BUTI and some similarities to HA-BUTI, as has previously
been suggested in UTI [19] and in studies undertaken on
bloodstream infections, pneumonia and endocarditis [10,12,13].
Taking these ﬁndings into account, empirical antimicrobial
therapy should cover ESBL-producing, amoxicillin-clavulanic-
resistant and ﬂuoroquinolone-resistant Enterobacteriaceae in
patients with HCA-BUTI in our country, at least in severe
forms. Although P. aeruginosa is not frequent in HCA-BUTI in
our series (4%), in a previous study it was more frequent (6%)
[16]. Because of this, P. aeruginosa probably has to be covered
in the more severe cases of HCA-BUTI. This statement should
be conﬁrmed in new studies trying to deﬁne subgroups of
HCA patients deserving antispseudomonals. As classically
recommended, in HA-BUTI empirical antipseudomonals
should be used because in this group P. aeruginosa is signiﬁ-
cantly more prevalent (16% in our series).
This study has some limitations. Only university tertiary-care
centres participated in the study. Therefore, our results,
theoretically, may not be fully extrapolated to other patient
populations receiving care in other types of facilities. Another
limitation is that only patients admitted to the hospital were
included. Studying patients discharged from the emergency room
could have added more complete information about the BUTI
population. However, ambulatory patients are more difﬁcult to
study, and we focused on patients needing hospital admission.
The growing frequency of ambulatory healthcare and the
higher mortality rate of HCA-BUTI means that new strategies
should also be applied to this population to improve the clinical
management of patients at risk of this infection.
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